Skip to content

CHICAGO–(BUSINESS WIRE)–Feb. 28, 2006–Allscripts (Nasdaq:MDRX)
announced that it closed its public offering of common stock today. In
the offering, Allscripts sold 8,395,000 shares of its common stock,
including 1,095,000 shares upon the exercise in full of the
underwriters’ option to purchase additional shares of common stock, at
a price per share of $17.75. After deducting underwriting discounts
and commissions, net proceeds to Allscripts were approximately $141.6
million.

Allscripts intends to use all of the net proceeds from the
offering to finance the proposed acquisition of A4 Health Systems,
Inc. If the acquisition is not consummated, the proceeds will be used
for general corporate purposes.

The offering was led by Lehman Brothers and UBS Investment Bank as
joint book-running managers. Jefferies Broadview, William Blair &
Company, Piper Jaffray and Goldman, Sachs & Co. were co-managers for
the offering.

A copy of the final prospectus supplement and accompanying
prospectus relating to the offering may be obtained, when available,
from Lehman Brothers, Prospectus Department, c/o ADP Financial
Services, Integrated Distribution Services, 1155 Long Island Avenue,
Edgewood, New York, NY 11717 and UBS Investment Bank, 299 Park Avenue,
New York, NY 10071. These documents are being filed with the
Securities and Exchange Commission and are available over the Internet
at the SEC’s web site at http://www.sec.gov.

About Allscripts

Allscripts is a provider of clinical software, connectivity and
information solutions that physicians use to improve healthcare.
Allscripts Clinical Solutions Group’s clinical software applications
include Electronic Health Record, e-prescribing and document imaging
solutions. Additionally, Allscripts provides clinical product
education and connectivity solutions for physicians and patients
through its Physicians Interactive(TM) Group and medical fulfillment
services through its Medication Solutions Group.

This announcement shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor shall there be any offer of these
securities in any jurisdiction in which such offer, solicitation or
sale would be unlawful prior to the registration or qualification
under the securities laws of any such jurisdiction.

Statements in this press release contain forward-looking
information within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, including
statements about the proposed acquisition and the intended use of
proceeds of the offering. These statements involve a number of risks
and uncertainties, including conditions in the financial markets and
customary closing conditions. For a more complete discussion of the
risks, uncertainties and assumptions that may affect Allscripts, see
the final prospectus supplement relating to the offering and
Allscripts’ 2004 Annual Report on Form 10-K, available through the Web
site maintained by the Securities and Exchange Commission at
www.sec.gov.


    CONTACT: Allscripts
             Bill Davis, 312-506-1211
             bill.davis@allscripts.com

    SOURCE: Allscripts
Scroll To Top